US 2024/0252526 A1 · TREATMENT OF HEMATOLOGICAL DISORDERS

Abstract

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

Claims7

Dependent claims

A method to treat a hematologic proliferative disorder in a subject, which method comprises administering to said subject a pharmaceutical composition comprising CPX-351 that supplies daunorubicin and cytarabine in a treatment cycle in combination with venetoclax.

Dependencies are inferred from the claim text.

Facts

Application

18/632,083Filed 10 Apr 2024

Priority

18 Nov 2020

Published

1 Aug 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/7068
Containing condensed or non-condensed pyrimidines: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/635
Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide: having a heterocyclic ring, e.g.…
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…

Family

Application63/115,540Us provisional application · filed 18 Nov 2020

Application17/530,245Continuation · filed 18 Nov 2021

Application18/632,083Continuation

US 11,980,636 B2Related patent

US 12,642,811 B2Related patent

US 2022/0152074 A1Published application

US 2024/0252526 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

18/632,083Filed 10 Apr 2024

Priority

18 Nov 2020

Published

1 Aug 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/7068
Containing condensed or non-condensed pyrimidines: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/635
Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide: having a heterocyclic ring, e.g.…
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…

Family

Application63/115,540Us provisional application · filed 18 Nov 2020

Application17/530,245Continuation · filed 18 Nov 2021

Application18/632,083Continuation

US 11,980,636 B2Related patent

US 12,642,811 B2Related patent

US 2022/0152074 A1Published application

US 2024/0252526 A1This patent

From the US filing history. Foreign family members aren’t listed.

Treatment of hematological disorders

Life of this patent

Abstract

Claims7

Treatment of hematological disorders

Life of this patent

Abstract

Claims7